

IONETIX AND ATONCO SIGN PARTNERSHIP AGREEMENT TO FIGHT BLADDER CANCER

Atonco (Nantes-Saint Herblain, France) and Ionetix (Lansing, MI) have signed a partnership agreement to ensure the manufacturing and GMP supply of the radiopharmaceutical product required for the successful completion of Atonco's clinical studies and commercialization in the United States.

Atonco, a clinical stage radiopharmaceutical company, aims to demonstrate through its clinical research program the relevance of a revolutionary therapeutic treatment, alpha immunotherapy, targeting non-muscle invasive bladder cancer.

IONETIX Corporation operates a North American GMP manufacturing and supply chain for alpha emitting radiopharmaceuticals. Through this agreement, Ionetix will provide its production capabilities for the radionuclide, astatine-211, and its network of radiopharmacies to manufacture patient doses according to Good Manufacturing Practices (GMP). The agreement includes the supply of the radioisotope, astatine-211, GMP manufacturing of injectable doses and specifies the terms of the FDA agent agreement signed in August 2021.

IONETIX leads the way in establishing the first commercial-scale supply of astatine-211 in North America from its cyclotron production facility in Lansing, MI.

"We are very excited about the partnership with Atonco, which will allow us to actively collaborate on its clinical development program and commercialization in the United States, subject to approval of Atonco's drug candidates," said David Eve, vice president of medical affairs.

"This partnership agreement is a key step in the development of Atonco," said Sylvain Fanier, President of Atonco. "We are convinced that Ionetix is the most reliable and advanced partner to ensure optimal supply for our clinical development and commercialization in North America. With their expertise and experience in manufacturing radiopharmaceuticals and in discussions with the FDA, Ionetix will greatly contribute to our joint success in offering bladder cancer patients a very promising therapeutic alternative.

About IONETIX

IONETIX is leveraging its growing network of radiopharmaceutical manufacturing sites to support the development and commercialization of targeted alpha therapy (TAT). This is an emerging cancer therapy using alpha radionuclides. TAT delivers high-energy alpha particles to cancer cells and the tumor microenvironment to treat cancer while preserving healthy tissue.

For more information, visit www.ionetix.com



About ATONCO

ATONCO is a privately held French company that develops targeted molecular radiation products for oncology applications. Originating from the world-class nuclear medicine cluster in Nantes, ATONCO and its academic partners are committed to the clinical use of alpha-emitting radionuclides, in particular astatine-211 (^{211}At).

For more information, visit www.atonco-pharma.com

Important Information This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States, or in any other jurisdiction in which such an offer would be illegal. The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933 (the "US Securities Act"), or under the securities laws of any state or other jurisdiction of the United States and may not be offered or sold within the United States, unless the securities have been registered under the US Securities Act or an exemption from the registration requirements of the US Securities Act is available